Palaniappan Kulanthaivel

Author

Eli Lilly (United States)

Also Known As

Kabanov, Alexander V., P Turner, PALANIAPPAN KULANTHAIVEL, Palaniappan Kulanthaivel

118

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Florida State University Dana-Farber Cancer Institute University of Georgia Institute of Minerals and Materials Technology

About

Palaniappan Kulanthaivel is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	24	868
2	Natural Sciences	14	18	583
3	Engineering	4	4	208
4	Health Sciences	1	1	12
5	Public Health	1	1	11

Palaniappan Kulanthaivel

Publications

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Cancer Discovery	2016	740
Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel, Drug Metabolism and Disposition	2015	270
Balanol: a novel and potent inhibitor of protein kinase C from the fungus Verticillium balanoides Palaniappan Kulanthaivel, Yali F. Hallock, Christie Boros, Journal of the American Chemical Society Fungal Cell BiologyPotent InhibitorAltmetric Attention ScoreMedicinal FungiChemical Biology	1993	211
SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5 Jennifer B. Dennison, Palaniappan Kulanthaivel, Robert J. Barbuch, Drug Metabolism and Disposition	2006	171
A Panel of Cytochrome P450 BM3 Variants to Produce Drug Metabolites and Diversify Lead Compounds Andrew M. Sawayama, Michael M. Y. Chen, Palaniappan Kulanthaivel, Chemistry - A European Journal Drug Lead DiversificationEngineeringMetabolomic ProfilingCytochrome P450 Bm3Drug Metabolites	2009	143
A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Clinical Cancer Research	2015	137
Metabolism of Capsaicin by Cytochrome P450 Produces Novel Dehydrogenated Metabolites and Decreases Cytotoxicity to Lung and Liver Cells Christopher A. Reilly, William J. Ehlhardt, David A. Jackson, Chemical Research in Toxicology	2003	131
Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncytiotrophoblast Sammanda Ramamoorthy, Puttur D. Prasad, Palaniappan Kulanthaivel, Biochemistry	1993	117
Discovery of Cercosporamide, a Known Antifungal Natural Product, as a Selective Pkc1 Kinase Inhibitor through High-Throughput Screening Andrea Sussman, Karen Huss, Li-Chun Chio, Eukaryotic Cell	2004	111
Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate Jill C. Chappell, P. Kellie Turner, Y. Anne Pak, Clinical Pharmacology & Therapeutics	2018	110

Page 1